



Open Access Indonesian Journal of Medical Reviews

Journal Homepage: <https://hmpublisher.com/index.php/OAIJMR>

Osteoarthritis Medication and Overview: A Narrative Review

Radiyah Umi Partan^{1*}

¹Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya/Dr. Mohammad Hoesin General Hospital, Palembang, Indonesia

ARTICLE INFO

Keywords:

Osteoarthritis
Diagnosis
Management
Degenerative disease
Arthropathy

*Corresponding author:

Radiyah Umi Partan

E-mail address:

radiandinadr@yahoo.co.id

The author has reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/oaijmr.v2i1.153>

ABSTRACT

Gout is a metabolic disease that is heterogeneous, often familial, metabolic disease associated with abnormal uric acid deposits in tissues and is initially characterized by recurrent acute arthritis, usually monoarticular, and later by chronic deforming arthritis. Urate deposition occurs when serum uric acid is saturated (that is, at greater than 6.8 mg/dL [404.5 μmol/L]). Hyperuricemia is caused by excess or underexcretion of uric acid, sometimes both. The disease is especially common in the Pacific islands, for example, the Philippines and Samoa. Acute gouty arthritis is sudden in onset and often occurs at night. It may develop without a clear precipitating cause or may follow a rapid increase or decrease in serum urate levels. Common precipitants are excess alcohol (especially beer), changes in drugs that affect urate metabolism, and, in hospitalized patients, fasting before medical procedures. This literature review presents gout arthritis, symptoms, and signs in general to the prognosis of this disease.

1. Introduction

Degenerative joint disease is divided into two types, primary and secondary.¹ Primary degenerative joint disease generally affects some or all of the following: the proximal interphalangeal (PIP) joints of the fingers, the carpometacarpal joints of the thumb, hip, knee, metatarsophalangeal (MTP) joint of the big toe, and the cervical and lumbar spine.² Meanwhile, the secondary degenerative joint disease can occur in any joint as a sequel to articular injury. Injuries may be acute, as in fractures; or chronic, due to overuse of joint or metabolic diseases, for example in hyperparathyroidism, hemochromatosis, ochronosis, or joint inflammation (rheumatoid arthritis).

Osteoarthritis has a dangerous onset. Initial symptoms may include articular stiffness, rarely

lasting more than 15 minutes. This symptom progresses to pain on movement of the affected joint, worsened by activity or weight-bearing and relieved by rest.³ Flexion contractures or varus knee deformities are not uncommon, and the enlarged bones of the DIP (Heberden node) and PIP (Bouchard node) are occasionally prominent (figure 1). There is no ankylosis, but the limitation of movement of the joint or the affected joint is common. Crepitus may often be felt over the knee. Joint effusion and other signs of articular inflammation are mild. However, in some cases, the effect of a one-way valve between the knee joint and the gastrocnemius-semimembranosus bursa can lead to an accumulation of synovial fluid, referred to as a popliteal (Baker) cyst.⁴



Figure 1. Osteoarthritis in a middle-aged woman with Heberden's nodes in the DIP joint. Swelling at the onset of PIP causes Bouchard's nodes.

Investigations in osteoarthritis

Laboratory findings

Osteoarthritis does not cause an increase in the erythrocyte sedimentation rate (ESR) or other laboratory signs of inflammation. Synovial fluid is non-inflammatory.⁵

Imaging

Radiographs may reveal joint space narrowing, osteophyte formation and marginal bone lip, and thickened dense subchondral bone. Bone cysts may also be present.⁵

Differential Diagnosis

Because articular inflammation is minimal and systemic manifestations are absent, degenerative joint disease is rarely confused with other inflammatory joint diseases. The distribution of joint involvement in the hands also helps differentiate osteoarthritis from rheumatoid arthritis. Osteoarthritis primarily affects the DIP and PIP joints and parts of the wrist and metacarpophalangeal (MCP) joints. Rheumatoid arthritis involves the wrist and the MCP and DIP joints. Furthermore, the enlarged joints become hard

and cold in osteoarthritis but supple and warm in rheumatoid arthritis. Skeletal symptoms occur due to degenerative changes in the joints, especially in the spine and can lead to metastatic neoplasia.²

Prevention of osteoarthritis

Weight loss reduces the risk of developing knee and hand symptoms of osteoarthritis. Correcting a leg length difference of more than 1 cm with modified shoes can prevent knee osteoarthritis from developing in the shorter leg.⁶

Management

General action

Patients with osteoarthritis of the hand can benefit from assistive devices and instructions on joint protection techniques; the belt is useful for them with symptoms of osteoarthritis of the first carpometacarpal joint. Patients with mild to moderate osteoarthritis of the knee or hip should participate in a regular exercise program (e.g., a supervised walking program, and hydrotherapy classes) and, if overweight, must lose weight. The use of assistive devices (e.g, a cane on the contralateral side) may

improve functional status.⁷

Medicines

Oral nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDs are more effective than acetaminophen for osteoarthritis but have greater toxicity. NSAIDs inhibit cyclooxygenase (COX), the enzyme that converts arachidonic acid to prostaglandins. Prostaglandins play an important role in promoting inflammation, but they also help maintain homeostasis in several organs—especially the stomach, where prostaglandin E functions as a local hormone responsible for gastric mucosal cytoprotection. COX exists in two isomers—COX-1, which is expressed continuously in many cells and is responsible for the homeostatic effects of prostaglandins, and COX-2, which is induced by cytokines and expressed in inflammatory tissues. Most NSAIDs inhibit both isomers. Celecoxib is the only selective COX-2 inhibitor currently available in the United States.⁸

Gastrointestinal toxicity, such as gastric ulceration, perforation, and gastrointestinal bleeding, is the most common serious side effect of NSAIDs. The overall rate of bleeding with NSAID use in the general population is low (1:6000 users or less) but is increased by risk factors for long-term use, higher doses of NSAIDs, corticosteroids or concomitant anticoagulants, presence of rheumatoid arthritis, history of peptic ulcer disease or alcoholism, and age over 70. Proton pump inhibitors and histamine type-2 receptor antagonists reduce the incidence of serious gastrointestinal toxicity and should be used for patients with risk factors for NSAID-induced gastrointestinal toxicity. Patients who have recently recovered from NSAID-induced bleeding gastric ulcers appear to be at high risk for rebleeding (approximately 5% at 6 months) when NSAIDs are reintroduced, even if prophylactic measures (such as proton pump inhibitors) are used. Compared with nonselective NSAIDs, celecoxib is less likely to cause upper gastrointestinal side effects, including bleeding.

All NSAIDs, including aspirin and celecoxib, can

produce toxicity, including interstitial nephritis, nephrotic syndrome, prerenal azotemia, and worsening hypertension. Hyperkalemia due to hyporeninemic hypoaldosteronism is rarely seen. The risk of renal toxicity is low but is increased by the following risk factors: age older than 60 years, history of renal disease, heart failure, ascites, and use of diuretics.⁹

All NSAIDs, except nonacetate salicylates and celecoxib, interfere with platelet function and prolong bleeding time. Aspirin irreversibly inhibits platelet function, so the effect of bleeding time is lost only when new platelets are made. In contrast, the effect of nonselective NSAIDs on platelet function is reversible and disappears as the drug is cleared. Concomitant administration of nonselective NSAIDs may impair aspirin's ability to acetylate platelets and thus may interfere with the cardioprotective effects of low-dose aspirin. The US Food and Drug Administration (FDA) has warned that all NSAIDs can increase the risk of myocardial infarction and stroke in patients with or without known risk factors for heart disease or heart disease. While cardiovascular risk is related to dose and duration of treatment, stroke and myocardial infarction can occur within the first week of treatment. The cardiovascular risks associated with moderate-dose naproxen, ibuprofen, and celecoxib (200 mg orally daily) are comparable. Chondroitin sulfate and glucosamine, alone or in combination, were no better than placebo in reducing pain in patients with knee or hip osteoarthritis.

Topical therapy

Topical NSAIDs (e.g, 4 g of 1% diclofenac gel applied to the affected joint four times daily) appear to be more effective than placebo for knee and hand osteoarthritis and has a lower rate of systemic side effects than oral NSAIDs. Topical NSAIDs are preferred for patients 75 years of age and older. Topical capsaicin may be beneficial for hand or knee osteoarthritis.¹⁰

Acetaminophen and opioids

Acetaminophen is not recommended because it

does not reduce pain and has a hepatotoxic effect at high doses. Opioids are generally not suitable for the long-term management of pain due to osteoarthritis.

Intra-articular injection

Many patients with moderately severe knee osteoarthritis who do not respond to NSAIDs receive intra-articular injections of corticosteroids, hyaluronic acid, or platelet-rich plasma. Although each of these can temporarily reduce pain, neither has conclusively produced long-term benefits in reducing pain or maintaining function. A 2-year controlled trial showed that injecting the knee with triamcinolone every 6 months was no more effective than injecting saline in reducing knee pain. The American College of Rheumatology does not recommend corticosteroid injections for osteoarthritis of the hand.^{11,12}

Duloxetine

For patients with osteoarthritis of the multiple joints who have not responded to or cannot use NSAIDs, the selective serotonin and norepinephrine reuptake inhibitor duloxetine, 30-60 mg orally daily, may reduce pain. The side effect of nausea occurs in 6-15% of patients.¹³

Surgery

Total hip and knee replacement provides excellent symptomatic and functional improvement when joint involvement severely limits walking or causes pain at rest, especially at night. Arthroscopic surgery for knee osteoarthritis is ineffective.

2. Conclusion

Osteoarthritis causes can be treated using modification of equipment, such as footwear or canes, or by administration of medication.

3. References

1. Lespasio MJ, Piuizzi NS, Husni ME, Muschler GF, Guarino AJ, et al. Knee osteoarthritis: a primary. *Perm J.* 2017; 21:16-183.

2. Mora JC, Przkora R, Cruz-Almeida Y. Knee osteoarthritis: pathophysiology and current treatment modalities. *JPain Res.* 2018; 11: 2189-96.
3. Chen D, Shen J, Zhao W, Wang T, Han L, et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanisms. *Bone Res.* 2017; 5:16044.
4. Ongkowijaya JA, Setiyohadi B, Sumariyono S. Erosive osteoarthritis. *Indo J Rheumatol.* 2018; 2(1).
5. Chinese Orthopedic Association. Diagnosis and treatment of osteoarthritis. *Orthop Surg.* 2010; 2(1):1-6.
6. Bannuru RR et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Cartilage Osteoarthritis.* 2019; 27(11):1578-89.
7. Filardo G, Kon E, Longo UG, Madry H, Marchettini P, et al. Non-surgical treatments for the management of early osteoarthritis. *Knee Surg Sports Traumatol Arthrosc.* 2016; 24(6):1775-85.
8. Grassel S, Muschter D. Recent advances in the treatment of osteoarthritis. *F1000Res.* 2020; 9.
9. Cooper C, Chapurlat R, Al-Daghri N, Herrero-Beaumont G, Bruyère O, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? *Drugs Aging.* 2019; 36(Suppl 1):15-24.
10. Revel FB, Fayet M, Hagen M. Topical diclofenac, an effective treatment for osteoarthritis: a narrative review. *Rheumatol Ther.* 2020; 7(2):217-36.
11. Jones IA, et al. Intra-articular treatment options for knee osteoarthritis. *Nat Rev Rheumatol.* 2019; 15(2):77-90.
12. Khan M et al. Cochrane in CORR®: intra-articular corticosteroid for knee osteoarthritis. *Clin Orthop Relat Res.* 2018; 476(7):1391-2.

13. Weng C, Xu J, Wang Q, Lu W, Liu Z. Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a systematic review and meta-analysis. *Cartilage Osteoarthritis*. 2020; 28(6):721-34.